Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus US stocks turned firmly into the red on Thursday as US-Iran fears spurred a continued rally in oil, with Walmart (WMT) earnings and Federal Reserve rate-cut odds in focus…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump administration is edging toward military conflict with Iran

    80% confidence

  • Talks between Tehran and Washington had reached a potential framework for a deal on Iran's nuclear program

    80% confidence

  • DoorDash expects marketplace GOV to be in range of $31.0 billion to $31.8 billion for Q1 2026

    80% confidence

  • US has largest air power armament in Middle East since invasion of Iraq in 2003

    80% confidence

  • Samsung is negotiating price for HBM4 at around $700 per unit, up to 30% higher than previous generation

    80% confidence

  • Walmart faces headwinds including tariffs, geopolitical conditions, and inflation in year ahead

    80% confidence

  • SK Hynix set price of HBM4 for Nvidia in mid-$500 range in August but may move to match Samsung's higher number

    80% confidence

  • DoorDash expects adjusted EBITDA to be in range of $675 million to $775 million for Q1 2026

    80% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · interest rate target range low3.5 percent
Board of Governors of the Federal Reserve System · interest rate target range high3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus — Source | Via News | Via News